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Purpose: Cancer and its treatment are recognized risk factors for venous thromboembolism 
(VTE); active cancer accounts for almost 20% of all newly diagnosed VTE. Inferior vena cava 
(IVC) filters are utilized to provide mechanical thromboprophylaxis to prevent pulmonary 
embolism (PE) or to avoid bleeding from systemic anticoagulation in high-risk situations. 
In this report, and utilizing a case study, we will address the appropriate utilization of such 
filters in cancer patients.
Methods: The case of a 43-year-old female patient with rectal cancer, who developed deep 
vein thrombosis following a complicated medical course, will be presented. The patient was 
anticoagulated with a low molecular weight heparin, but a few months later and following an 
episode of bleeding, an IVC filter was planned. Using the PubMed database, articles published 
in English language addressing issues related to IVC filters in cancer patients were accessed 
and will be presented.
Results: Many recent studies questioned the need to insert IVC filters in advanced-stage cancer 
patients, particularly those whose anticipated survival is short and prevention of PE may be of 
little clinical benefit and could be a poor utilization of resources.
Conclusion: Systemic anticoagulation can be safely offered for the majority of cancer patients. 
When the risk of bleeding or pulmonary embolism is high, IVC filters can be utilized. However, 
placement of such filters should take into consideration the stage of disease and life expectancy 
of such patients.
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Case presentation
Our patient is a 43-year-old woman who was first diagnosed with rectal cancer seven 
years ago. She was treated with neoadjuvant chemotherapy and radiation therapy 
that lasted three months following which she underwent low anterior resection with 
ileostomy that was followed by adjuvant chemotherapy. Following the completion of 
her chemotherapy she underwent secondary anastomosis (ileoanal Hartmann’s pouch 
anastomosis).
Two years later, she had disease recurrence in retroperitoneal lymph nodes and was 
treated by chemotherapy. A month after stopping treatment, she was found to have 
further disease progression manifested by new sacral mass and more retroperitoneal 
lymph nodes. At this time, radiotherapy to the sacral mass was given, and   chemotherapy 
was restarted and continued for six months. Five weeks later, she presented with left 
lower limb pain, swelling, and redness; iliofemoral deep vein thrombosis (DVT) 
was confirmed by Doppler ultrasound for which she was put on therapeutic doses of Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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  low-molecular-weight heparin (LMWH). Disease   evaluation 
at this time showed disease progression in para-aortic lymph 
nodes and new right hydronephrosis. She had a double 
J catheter placed, and additional chemotherapy was started, 
with no success, however, in controlling her disease. Another 
oral chemotherapy regimen failed too, with imaging studies 
showing a new adrenal metastasis and a large destructive 
mass lesion involving the S1–S2 segment compressing the 
left nerve roots.
Given the poor response to many lines of chemotherapy 
and the poor outcome associated with her disease, she 
was transferred to palliative care for best supportive care. 
The patient’s overall prognosis was discussed with her in 
details, and she elected to have a “do not resuscitate” (DNR) 
status.
A few weeks later, she was admitted in order to   control 
her increasing pain with intravenous narcotic   infusion. 
  During her hospital stay and while on LMWH, she   developed 
  hematuria; urine analysis showed numerous red blood cells 
and 20 white blood cells, and the urine culture was positive for 
Escherichia coli for which she was treated with antibiotics. 
Microscopic hematuria continued, and the primary team 
planned insertion of an inferior vena cava (IVC) filter.
Discussion
Venous thromboembolism (VTE), which represents a 
spectrum of diseases including DVT and pulmonary 
  embolism (PE), occurs more frequently in cancer patients. 
Cancer and its treatment are recognized risk factors for VTE; 
some studies have reported a six-fold increased risk of VTE in 
cancer patients compared with those without.1 Active cancer 
accounts for almost 20% of all new VTE events occurring 
in the community.2 The risk varies by cancer type, and is 
especially high among patients with malignant brain tumors 
and adenocarcinoma of the ovary, pancreas, colon, stomach, 
lung, prostate, and kidney.3
Treatment of VTE typically includes initial anticoagula-
tion with unfractionated heparin, a low molecular weight 
heparin, or a pentasaccharide-like fondaparinux,4 along with 
vitamin K antagonists like warfarin. Thrombolytic agents 
may be used in severe cases. Occasionally, specific   clinical 
situations present in which the risk of PE is very high or 
systemic anticoagulation may be associated with high risk 
of bleeding; in these instances, IVC filters are utilized to 
provide mechanical thromboprophylaxis to prevent PE, 
the life-threatening complication of VTE. Such filters are 
inserted using a relatively noninvasive technique to maintain 
central flow. Thanks to newer technology, the IVC filters 
are becoming a very attractive option and can function with 
anticoagulation to optimize the prophylaxis strategy.
Inferior vena cava filters are usually utilized in many 
clinical situations (Table 1).5,6 However, many of these 
  indications are subjective, and consensus may occasionally 
be difficult to reach. In a community-based study, researchers 
at McMaster University reviewed 1547 local county residents 
with confirmed diagnosis of acute VTE and without a prior 
IVC filter. Following the VTE, 203 (13.1%) patients had 
an IVC filter placed. In reviewing the indications for IVC 
filter placement, panel members unanimously agreed that 
the use of an IVC filter was appropriate in 51% of the cases 
and inappropriate in 26%; no consensus was reached in the 
remaining 23% of the cases.7
The clinical benefit of IVC filter placement was addressed 
in one prospective trial (the PREPIC study) in which 
400 patients with proximal DVT who were at risk for PE 
were randomized to receive an IVC filter (200 patients) or 
no filter (200 patients). Both groups were anticoagulated 
with LMWH or unfractionated heparin. At day 12, two 
(1.1%) patients assigned to receive filters, as compared 
with nine (4.8%) patients assigned to receive no filters, had 
symptomatic or asymptomatic PE (odds ratio [OR], 0.22; 
95% confidence interval [CI]: 0.05–0.90). However, at 
2 years, 37 (20.8%) patients assigned to the filter group, as 
compared with 21 (11.6%) patients assigned to the no-filter 
group, had recurrent DVT (OR 1.87; 95% CI: 1.10–3.20).8 
This study was updated eight years later; patients with 
IVC filters experienced a greater cumulative incidence of 
symptomatic DVT (35.7% versus 27.5%; hazard ratio [HR] 
1.52, CI: 1.02–2.27; P = 0.042), but significantly fewer 
symptomatic pulmonary emboli (6.2% versus 15.1%; HR 
0.37, CI: 0.17–0.79; P = 0.008).9 The conclusion from this 
Table 1 Indications for IVC filter placement
• Main indications
   Failure of anticoagulation: recurrent VTE despite anticoagulation
   Contraindications and/or severe complications of anticoagulation
   High risk for bleeding
   Real bleeding (Gi, Gu, GYn, CnS)
   Thrombocytopenia (depends on count and etiology)
   immediate postoperative VTE
   Large CnS tumor: primary or metastatic
• Other indications
   Large, free-floating iliocaval thrombus
   Limited cardiopulmonary reserve (Cor Pulmonale)
   Poor compliance with medications
   Patients at risk for falls while on anticoagulation therapy
Abbreviations:  iVC,  inferior  vena  cava;  Gi,  gastrointestinal;  Gu,  genitourinary;   
GYn, gynecological; CnS, central nervous system; VTE, venous thromboembolism.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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long-term follow-up was similar to the original report; that is, 
with an IVC filter there is an equivalent trade-off of fewer 
PE at the cost of more DVTs. There was no difference in 
long-term morbidity or mortality in both groups.
Given the lack of long-term benefits of IVC filters, tempo-
rary, retrievable filters have gained increasing interest. Many 
different retrievable filters have recently received approval for 
temporary insertion. Recent data suggest that the use of these 
filters may be associated with low rates of PE and insertion 
complications.10 Nevertheless, no randomized clinical trials 
have been performed. In one large retrospective study that 
included 252 evaluable patients who had retrievable filter 
placed for different indications, only 47 filters were success-
fully retrieved, yielding a retrieval rate of 18.7%.11 Similar or 
higher retrieval rates were reported by others.12
Regardless of the type of the filter placed, the most recent 
American Colleague of Chest Physicians (ACCP) guidelines 
recommend systemic anticoagulation, when possible, even 
with the filter in place.13
Cancer itself, or its treatment, may result in certain clinical 
complications that make systemic anticoagulation very risky. 
Venous thromboembolic disease is a frequent complication in 
patients with intracranial malignancies. Many of the primary 
brain tumors like gliomas or secondary metastatic tumors to 
the brain are either bulky or very vascular, thus increasing the 
risk of bleeding with or without systemic anticoagulation.14 
Brain metastases from melanoma, choriocarcinoma, thyroid 
carcinoma, and renal cell carcinoma have particularly high 
propensities for spontaneous hemorrhage, while metastatic 
tumors from sites like the lung and breast are less likely 
to bleed spontaneously.15 However, not all patients with 
intracranial malignancies are at higher risk of bleeding with 
anticoagulation. The complication rate of IVC filters in 
patients with brain tumors is higher than commonly perceived 
and may outweigh the risk of anticoagulation. Researchers 
at Brigham and Women’s Hospital in Boston reviewed the 
records of 49 patients with intracranial malignancies and 
venous thromboembolic disease to determine the effectiveness 
and complications resulting from systemic anticoagulation or 
IVC filter placement. Of the 42 patients who received IVC 
filters, a strikingly high percentage (62%) developed one or 
more complications; 12% developed recurrent PE, while 57% 
developed filter thrombosis, recurrent DVT, or postphlebitic 
syndrome. These complications severely reduced the quality 
of life of affected patients. Only 15 (31%) patients were 
treated with anticoagulation, and seven of these received it 
because of continued thromboembolic disease. None of these 
15 patients had proven hemorrhagic complications.16
Many recent studies questioned the need to insert IVC 
  filters in cancer patients, particularly those with advanced-
stage disease whose survival is short, and prevention of 
PE may be of little clinical benefit and could be a poor 
  utilization of resources. In one retrospective study performed 
to determine the clinical benefit of IVC filter placement in 
patients with malignancy, 116 patients who had such filters 
inserted were included. A total of 91 (78%) patients had stage 
IV disease, 42 (46%) of them died of cancer within six weeks, 
and only 16 (14%) were alive at one year.17
The benefits of IVC filter placement on overall survival, 
as measured from the time of VTE, was addressed in a 
recent retrospective study that examined 206 consecutive 
cancer patients with VTE. Patients were classified into 
three treatment groups: anticoagulation-only (n = 62), IVC 
  filter-only (n = 77), or a combination of both IVC filter 
and anticoagulation (n = 67). Median overall survival was 
significantly greater in patients treated with anticoagulation 
(13 months) compared with those treated with IVC filters (two 
months) or combination of both (3.25 months; P , 0.0002). 
IVC patient’s risk of death was at 1.9 times more than 
anticoagulation only (HR = 0.528; 95% CI: 0.374–0.745). 
Multivariate analysis revealed that performance status and 
type of thrombus were not confounders and had no effect 
on overall survival.18
In another study, the survival benefit of placing IVC 
filters in patients with late-stage malignancy was   evaluated 
in a group of 5970 patients who were treated with a 
  primary   diagnosis of malignancy at a tertiary care facility. 
Retrospective analysis identified 55 consecutive patients 
with stage III or IV malignant disease and VTE who received 
IVC filters. In a case control study, 16 patients with VTE 
but without IVC filter were matched for age, sex, type of 
malignancy, and stage of disease. Filter placement prevented 
PE in 52 (94.5%) patients, however, four (7.3%) patients 
had complications related to the procedure; 13 (23.6%) 
patients with late-stage cancer survived less than 30 days 
following the placement of the filter; another 13 (23.6%) 
patients of this group, however, survived more than one 
year. Ambulatory status differed significantly (P = 0.01) 
between these two subgroups. Authors concluded that IVC 
filter placement conferred no survival benefit compared 
with the control group and that the survival of such patients 
with advanced-stage cancer was limited primarily by the 
malignant process.19 Researchers at MD Anderson Cancer 
Center concluded, in a study that included 308 cancer patients 
with VTE and IVC filters, that such filters are safe and 
effective in   preventing PE-related deaths in selected patients Therapeutics and Clinical Risk Management
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with cancer. However, patients with a history of DVT and 
bleeding or advanced   disease had the lowest survival after 
IVC filter placement.20
Conclusion
Venous thromboembolism is commonly encountered in 
cancer patients. While systemic anticoagulation can be safely 
offered for the majority of such patients, the risk of bleeding 
or PE can be occasionally high. Placement of IVC filters in 
cancer patients should take into consideration the stage of 
disease and their life expectancy. While such filters can be 
effective in preventing PE, there may be limited survival 
benefit in patients with advanced-stage malignancies. Many 
studies have suggested that the placement of IVC filters in 
such patients does not improve survival and may negatively 
affect the quality of life. In our case under discussion, 
a   decision was made not to insert a filter and the patient died 
two weeks later.
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